Morgans Senior Analyst Scott Power caught up with Robert Proulx, Chief Executive Officer of Imagion Biosystems, who explained with he joined the company and the technology behind it.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal